Skip to main content

Editas Medicine, Inc.

EDIT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001650664

In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $386.3M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Editas Medicine, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
314
No complete 13F data for Q4 2020
Shares held
53.2M
No complete 13F data for Q4 2020
Total value
$2.23B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting EDIT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 314 institutions
Q1 2021: 314 institutionsQ2 2021: 316 institutionsQ3 2021: 321 institutionsQ4 2021: 307 institutionsQ1 2022: 257 institutionsQ2 2022: 258 institutionsQ3 2022: 265 institutionsQ4 2022: 251 institutionsQ1 2023: 236 institutionsQ2 2023: 238 institutionsQ3 2023: 222 institutionsQ4 2023: 226 institutionsQ1 2024: 226 institutionsQ2 2024: 236 institutionsQ3 2024: 230 institutionsQ4 2024: 207 institutionsQ1 2025: 195 institutionsQ2 2025: 194 institutionsQ3 2025: 194 institutionsQ4 2025: 197 institutionsQ1 2026: 208 institutionsQ2 2026: 215 institutions
Value heldQ1 2021: $2.23B
Q1 2021: $2.23BQ2 2021: $2.96BQ3 2021: $2.17BQ4 2021: $1.36BQ1 2022: $862.3MQ2 2022: $561.5MQ3 2022: $590.5MQ4 2022: $479.3MQ1 2023: $384.0MQ2 2023: $516.8MQ3 2023: $481.0MQ4 2023: $595.7MQ1 2024: $503.8MQ2 2024: $263.3MQ3 2024: $187.7MQ4 2024: $64.8MQ1 2025: $51.0MQ2 2025: $90.9MQ3 2025: $149.3MQ4 2025: $102.5MQ1 2026: $127.5MQ2 2026: $386.3M
Institutions holding EDIT and their total value by quarter
QuarterHoldersValue
Q2 2026215$386.3M
Q1 2026208$127.5M
Q4 2025197$102.5M
Q3 2025194$149.3M
Q2 2025194$90.9M
Q1 2025195$51.0M
Q4 2024207$64.8M
Q3 2024230$187.7M
Q2 2024236$263.3M
Q1 2024226$503.8M
Q4 2023226$595.7M
Q3 2023222$481.0M
Q2 2023238$516.8M
Q1 2023236$384.0M
Q4 2022251$479.3M
Q3 2022265$590.5M
Q2 2022258$561.5M
Q1 2022257$862.3M
Q4 2021307$1.36B
Q3 2021321$2.17B
Q2 2021316$2.96B
Q1 2021314$2.23B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Editas Medicine, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding EDIT in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Two Sigma Investments, LP813,890$34.2M0.10%––
Credit Suisse AG902,203$37.9M0.03%––
Goldman Sachs Group Inc907,979$38.1M0.01%––
JPMorgan Chase & Co965,469$40.5M0.01%––
Morgan Stanley966,297$40.6M0.01%––
Geode Capital Management, LLC1,153,365$48.4M0.01%––
Capital World Investors1,300,000$54.6M0.01%––
State Street Corp2,323,718$97.6M0.01%––
Sumitomo Mitsui Trust Holdings, Inc.4,222,802$177.4M0.11%––
Nikko Asset Management Americas, Inc.4,257,556$178.8M0.88%––
BlackRock Inc.5,737,376$241.0M0.01%––
Vanguard Group Inc6,347,754$266.6M0.01%––
ARK Investment Management LLCSuperinvestorARK Invest8,751,923$367.6M0.73%––
Westside Investment Management, Inc.3,650––––